SBSudha B. Biddinger

Sudha B. Biddinger

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sudha B. Biddinger has a total of 134 co-authors. Here are the top co-authors by number of shared publications:

  • Ji Miao

    Division of Endocrinology (I.S., A.E.L., J.K., M.E.G., A.V.L., J.M., S.S.A., D.-J.S., S.C., S.B.B.), Boston Children’s Hospital, Harvard Medical School, MA

    8 shared publications
  • Amy E. Levenson

    Division of Endocrinology (I.S., A.E.L., J.K., M.E.G., A.V.L., J.M., S.S.A., D.-J.S., S.C., S.B.B.), Boston Children’s Hospital, Harvard Medical School, MA

    6 shared publications
  • Mary E. Haas

    16Regeneron Genetics Center, Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA

    6 shared publications
  • Joanna Krawczyk

    Division of Endocrinology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA

    5 shared publications
  • Sarah D. de Ferranti

    Department of Cardiology (S.D.d.F.), Boston Children’s Hospital, Harvard Medical School, MA

    5 shared publications
  • Amy S. Shah

    Division of Endocrinology Cincinnati Children's Hospital Medical Center and University of Cincinnati Cincinnati Ohio USA

    4 shared publications

Latest Publications

  • Open Access

    The diabetes gene Tcf7l2 organizes gene expression in the liver and regulates amino acid metabolism

    by Joanna Krawczyk, William O’COnnor, Pedro Vendramini, Mareike Schell, Kiran J. Biddinger, Matt Kanke, George Pengo, Ivana Semova, Tiffany Fougeray, Marcia Haigis, et al.


  • Top Cited Papers

    MASLD in children: integrating epidemiological trends with mechanistic and translational advances

    by Jeffrey B. Schwimmer, Sudha B. Biddinger, Samar H. Ibrahim

    Metabolic dysfunction–associated steatotic liver disease (MASLD) is the most common pediatric liver disease, affecting approximately 10% of children. Its prevalence is rising at an alarming rate, with cases increasingly identified even in early childhood. While MASLD shares key features across the lifespan, its earlier onset reflects developmental vulnerabilities and unique mechanistic drivers. Perinatal influences, including maternal obesity, gestational diabetes, and early-life nutritional exposures, play a central role by disrupting metabolic programming, driving mitochondrial dysfunction, and inducing epigenetic modifications. These early stressors interact with genetic predispositions, such as PNPLA3 and TM6SF2 variants, to amplify susceptibility and shape disease severity. Pediatric MASLD also exhibits distinct histological features, particularly predominant periportal (zone 1) steatosis, inflammation, and fibrosis, which contrast with the centrilobular or pericentral (zone 3) patterns often seen in adults. These findings provide insight into spatial heterogeneity, developmental pathophysiology, and unique disease progression trajectories in children. Addressing MASLD in children requires pediatric-specific approaches to diagnosis, risk stratification, and intervention. By integrating epidemiological trends, mechanistic insights, and translational advances, this Review highlights opportunities for targeted therapies and prevention strategies aimed at mitigating early-life drivers of MASLD, reducing disease burden, and improving long-term outcomes.


  • Open Access

    The Diabetes Gene Tcf7l2 Organizes Gene Expression in the Liver and Regulates Amino Acid Metabolism

    by Joanna Krawczyk, William O’connor, Pedro Vendramini, Mareike Schell, Kiran J. Biddinger, George Pengo, Tiffany Fougeray, Krishna G. Aragam, Marcia Haigis, Wouter H. Lamers, et al.

    TCF7L2 harbors the strongest genetic association with diabetes identified thus far. However, its function in liver has remained unclear. Here, we find using mice with liver-specific deletion, that Tcf7l2 plays a central role in maintaining hepatic zonation. That is, in the normal liver, many genes show gradients of expression across the liver lobule; in the absence of Tcf7l2 , these gradients collapse. One major consequence is the disorganization of glutamine metabolism, with a loss of the glutamine production program, ectopic expression of the glutamine consumption program, and a decrease in glutamine levels. In parallel, metabolomic profiling shows glutamine to be the most significantly decreased metabolite in individuals harboring the rs7903146 variant in TCF7L2 . Taken together, these data indicate that hepatic TCF7L2 has a secondary role in glycemic control, but a primary role in maintaining transcriptional architecture and glutamine homeostasis.


  • Top Cited Papers

    Inhibition of nonalcoholic fatty liver disease in mice by selective inhibition of mTORC1

    by Bridget S. Gosis, Shogo Wada, Chelsea Thorsheim, Kristina Li, Sunhee Jung, Joshua H. Rhoades, Yifan Yang, Jeffrey Brandimarto, Li Li, Kahealani Uehara, et al.

    Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) remain without effective therapies. The mechanistic target of rapamycin complex 1 (mTORC1) pathway is a potential therapeutic target, but conflicting interpretations have been proposed for how mTORC1 controls lipid homeostasis. We show that selective inhibition of mTORC1 signaling in mice, through deletion of the RagC/D guanosine triphosphatase–activating protein folliculin (FLCN), promotes activation of transcription factor E3 (TFE3) in the liver without affecting other mTORC1 targets and protects against NAFLD and NASH. Disease protection is mediated by TFE3, which both induces lipid consumption and suppresses anabolic lipogenesis. TFE3 inhibits lipogenesis by suppressing proteolytic processing and activation of sterol regulatory element–binding protein-1c (SREBP-1c) and by interacting with SREBP-1c on chromatin. Our data reconcile previously conflicting studies and identify selective inhibition of mTORC1 as a potential approach to treat NASH and NAFLD.


  • Insulin Prevents Hypercholesterolemia by Suppressing 12α-Hydroxylated Bile Acids

    by Ivana Semova, Amy E. Levenson, Joanna Krawczyk, Kevin Bullock, Mary E. Gearing, Alisha V. Ling, Kathryn A. Williams, Ji Miao, Stuart S. Adamson, Dong-Ju Shin, et al.

    Background: The risk of cardiovascular disease in type 1 diabetes remains extremely high, despite marked advances in blood glucose control and even the widespread use of cholesterol synthesis inhibitors. Thus, a deeper understanding of insulin regulation of cholesterol metabolism, and its disruption in type 1 diabetes, could reveal better treatment strategies. Methods: To define the mechanisms by which insulin controls plasma cholesterol levels, we knocked down the insulin receptor, FoxO1, and the key bile acid synthesis enzyme, CYP8B1. We measured bile acid composition, cholesterol absorption, and plasma cholesterol. In parallel, we measured markers of cholesterol absorption and synthesis in humans with type 1 diabetes treated with ezetimibe and simvastatin in a double-blind crossover study. Results: Mice with hepatic deletion of the insulin receptor showed marked increases in 12α-hydroxylated bile acids, cholesterol absorption, and plasma cholesterol. This phenotype was entirely reversed by hepatic deletion of FoxO1 . FoxO1 is inhibited by insulin and required for the production of 12α-hydroxylated bile acids, which promote intestinal cholesterol absorption and suppress hepatic cholesterol synthesis. Knockdown of Cyp8b1 normalized 12α-hydroxylated bile acid levels and completely prevented hypercholesterolemia in mice with hepatic deletion of the insulin receptor (n=5–30), as well as mouse models of type 1 diabetes (n=5–22). In parallel, the cholesterol absorption inhibitor, ezetimibe, normalized cholesterol absorption and low-density lipoprotein cholesterol in patients with type 1 diabetes as well as, or better than, the cholesterol synthesis inhibitor, simvastatin (n=20). Conclusions: Insulin, by inhibiting FoxO1 in the liver, reduces 12α-hydroxylated bile acids, cholesterol absorption, and plasma cholesterol levels. Thus, type 1 diabetes leads to a unique set of derangements in cholesterol metabolism, with increased absorption rather than synthesis. These derangements are reversed by ezetimibe, but not statins, which are currently the first line of lipid-lowering treatment in type 1 diabetes. Taken together, these data suggest that a personalized approach to lipid lowering in type 1 diabetes may be more effective and highlight the need for further studies specifically in this group of patients.


  • Markers of cholesterol synthesis are elevated in adolescents and young adults with type 2 diabetes

    by Ivana Semova, Amy E. Levenson, Joanna Krawczyk, Kevin Bullock, Kathryn A. Williams, R. Paul Wadwa, Philip R. Khoury, Thomas R. Kimball, Elaine M. Urbina, Sarah D. Ferranti, et al.

    Background Changes in cholesterol absorption and cholesterol synthesis may promote dyslipidemia and cardiovascular disease in individuals with type 2 diabetes mellitus (T2DM). Objective To assess cholesterol synthesis and absorption in lean individuals, obese individuals, and individuals with T2DM. Methods We measured lathosterol and lanosterol (markers of cholesterol synthesis) as well as campesterol and β‐sitosterol (markers of cholesterol absorption) in the serum of 15‐26 years old individuals with T2DM (n = 95), as well as their lean (n = 98) and obese (n = 92) controls. Results Individuals with T2DM showed a 51% increase in lathosterol and a 65% increase in lanosterol compared to lean controls. Similarly, obese individuals showed a 31% increase in lathosterol compared to lean controls. Lathosterol and lanosterol were positively correlated with body mass index, fasting insulin and glucose, serum triglycerides, and C‐reactive protein, and negatively correlated with HDL‐cholesterol. In contrast, campesterol and β‐sitosterol were not altered in individuals with T2DM. Moreover, campesterol and β‐sitosterol were negatively correlated with body mass index, fasting insulin, and C‐reactive protein and were positively correlated with HDL‐cholesterol. Conclusions Adolescents and young adults with T2DM show evidence of increased cholesterol synthesis compared to non‐diabetic lean controls. These findings suggest that T2DM may promote cardiovascular disease by increasing cholesterol synthesis, and provide additional rationale for the use of cholesterol synthesis inhibitors in this group.


  • Top Cited Papers

    Trimethylamine N-Oxide Binds and Activates PERK to Promote Metabolic Dysfunction

    by Sifan Chen, Ayana Henderson, Michael C. Petriello, Kymberleigh A. Romano, Mary Gearing, Ji Miao, Mareike Schell, Walter J. Sandoval-Espinola, Jiahui Tao, Bingdong Sha, et al.


  • Type 1 diabetes is associated with an increase in cholesterol absorption markers but a decrease in cholesterol synthesis markers in a young adult population

    by Ivana Semova, Amy E. Levenson, Joanna Krawczyk, Kevin Bullock, Kathryn A. Williams, R. Paul Wadwa, Amy S. Shah, Philip R. Khoury, Thomas R. Kimball, Elaine M. Urbina, et al.


  • Open Access

    Fructose and glucose can regulate mammalian target of rapamycin complex 1 and lipogenic gene expression via distinct pathways

    by Yue Hu, Ivana Semova, Xiaowei Sun, Hong Kang, Satyapal Chahar, Anthony N. Hollenberg, David Masson, Matthew D. Hirschey, Ji Miao, Sudha B. Biddinger